CareDx Inc
CDNA14.770USD
+0.470+3.29%
Handelsschluss 09/18, 16:00（ET）Kurse um 15 Minuten verzögert
786.06MMarktkapitalisierung
15.21KGV TTM
mehr Informationen über CareDx Inc Unternehmen
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Company’s product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Unternehmensinformationen
BörsenkürzelCDNA
Name des UnternehmensCareDx Inc
IPO-datumJul 17, 2014
CEOMr. John W. Hanna
Anzahl der mitarbeiter644
WertpapierartOrdinary Share
GeschäftsjahresendeJul 17
Addresse8000 Marina Blvd
StadtBRISBANE
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl94005
Telefon14152872300
Websitehttps://www.caredx.com/
BörsenkürzelCDNA
IPO-datumJul 17, 2014
CEOMr. John W. Hanna
Führungskräfte
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-3.24%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+9.13%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
143.65K
+0.86%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
109.63K
-4.11%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
42.00K
--
Ms. Christine M. Cournoyer
Ms. Christine M. Cournoyer
Independent Director
Independent Director
38.58K
+45.71%
Mr. Jeffrey Adam Novack
Mr. Jeffrey Adam Novack
General Counsel, Secretary
General Counsel, Secretary
25.20K
-18.08%
Ms. Caroline Corner
Ms. Caroline Corner
Investor Relations
Investor Relations
--
--
Ms. Jennifer Foley
Ms. Jennifer Foley
Chief Product Officer
Chief Product Officer
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Peter Maag, Ph.D.
Dr. Peter Maag, Ph.D.
Independent Director
Independent Director
298.28K
-3.24%
Dr. Frederick E. (Fred) Cohen, M.D.
Dr. Frederick E. (Fred) Cohen, M.D.
Independent Director
Independent Director
144.69K
+9.13%
Mr. Michael D. Goldberg
Mr. Michael D. Goldberg
Independent Chairman of the Board
Independent Chairman of the Board
143.65K
+0.86%
Ms. Jessica Meng
Ms. Jessica Meng
Chief Commercial Officer
Chief Commercial Officer
109.63K
-4.11%
Mr. William A. (Bill) Hagstrom
Mr. William A. (Bill) Hagstrom
Independent Director
Independent Director
43.41K
--
Mr. Nathan Smith
Mr. Nathan Smith
Chief Financial Officer
Chief Financial Officer
42.00K
--
Umsatzaufteilung
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Testing Service revenue
61.92M
0.00%
Digital and other revenue
11.95M
0.00%
Product revenue
10.81M
0.00%
Nach RegionUSD
Name
Umsatz
Anteil
United States
79.86M
0.00%
Rest of the world
4.82M
0.00%
Nach Geschäftsbereich
Nach Region
Nach GeschäftsbereichUSD
Name
Umsatz
Anteil
Testing Service revenue
61.92M
0.00%
Digital and other revenue
11.95M
0.00%
Product revenue
10.81M
0.00%
Aktionärsstatistik
Aktualisiert: Fri, Aug 15
Aktualisiert: Fri, Aug 15
Aktionäre
Aktionärstypen
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.21%
BlackRock Institutional Trust Company, N.A.
7.64%
Baron Capital Management, Inc.
4.58%
State Street Global Advisors (US)
4.10%
Gagnon Securities LLC
4.01%
Andere
70.48%
Aktionäre
Aktionäre
Anteil
The Vanguard Group, Inc.
9.21%
BlackRock Institutional Trust Company, N.A.
7.64%
Baron Capital Management, Inc.
4.58%
State Street Global Advisors (US)
4.10%
Gagnon Securities LLC
4.01%
Andere
70.48%
Aktionärstypen
Aktionäre
Anteil
Investment Advisor/Hedge Fund
44.31%
Investment Advisor
43.78%
Hedge Fund
10.63%
Individual Investor
3.65%
Research Firm
2.34%
Pension Fund
0.66%
Bank and Trust
0.37%
Insurance Company
0.04%
Institutionelle Beteiligung
Aktualisiert: Tue, Jul 1
Aktualisiert: Tue, Jul 1
Berichtszeitraum
Anzahl der Institutionen
Gehaltenen Aktien
Anteil
Veränderung
2025Q2
458
57.19M
107.22%
-3.81M
2025Q1
463
58.20M
104.56%
-2.86M
2024Q4
457
54.99M
99.23%
-4.48M
2024Q3
452
53.78M
101.72%
-11.43M
2024Q2
424
54.82M
104.96%
-13.18M
2024Q1
450
55.58M
107.13%
-14.92M
2023Q4
462
54.27M
100.29%
-16.52M
2023Q3
493
55.98M
103.34%
-21.97M
2023Q2
517
57.57M
107.02%
-21.82M
2023Q1
532
58.67M
109.28%
-16.17M
Mehr Anzeigen
Aktionärsaktivitäten
Name
Gehaltenen Aktien
Anteil
Veränderung
Änderung%
Datum
The Vanguard Group, Inc.
4.82M
8.66%
-25.66K
-0.53%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.21M
7.56%
-77.53K
-1.81%
Mar 31, 2025
Baron Capital Management, Inc.
2.19M
3.93%
-17.29K
-0.78%
Mar 31, 2025
State Street Global Advisors (US)
2.48M
4.46%
-174.50K
-6.56%
Mar 31, 2025
Gagnon Securities LLC
1.42M
2.55%
-9.51K
-0.66%
Mar 31, 2025
ARK Investment Management LLC
2.35M
4.22%
-61.72K
-2.56%
Mar 31, 2025
Ophir Asset Management Pty Ltd
1.62M
2.91%
+1.62M
--
Mar 31, 2025
Hood River Capital Management LLC
1.58M
2.84%
+1.58M
--
Mar 31, 2025
Invesco Advisers, Inc.
1.88M
3.39%
+1.12M
+147.36%
Mar 31, 2025
Geode Capital Management, L.L.C.
1.28M
2.3%
+46.16K
+3.74%
Mar 31, 2025
Mehr Anzeigen
Verbundene ETFs
Aktualisiert: Tue, Sep 2
Aktualisiert: Tue, Sep 2
Name
Anteil
ARK Genomic Revolution ETF
2.49%
Invesco Biotechnology & Genome ETF
1.9%
ROBO Global Healthcare Technology & Innovation ETF
0.87%
Invesco Dorsey Wright Healthcare Momentum ETF
0.84%
Global X Genomics & Biotechnology ETF
0.78%
Franklin Genomic Advancements ETF
0.29%
First Trust Small Cap Growth AlphaDEX Fund
0.23%
SPDR S&P Biotech ETF
0.22%
VictoryShares US Small Mid Cap Value Momentum ETF
0.16%
iShares Micro-Cap ETF
0.15%
Mehr Anzeigen
ARK Genomic Revolution ETF
Anteil2.49%
Invesco Biotechnology & Genome ETF
Anteil1.9%
ROBO Global Healthcare Technology & Innovation ETF
Anteil0.87%
Invesco Dorsey Wright Healthcare Momentum ETF
Anteil0.84%
Global X Genomics & Biotechnology ETF
Anteil0.78%
Franklin Genomic Advancements ETF
Anteil0.29%
First Trust Small Cap Growth AlphaDEX Fund
Anteil0.23%
SPDR S&P Biotech ETF
Anteil0.22%
VictoryShares US Small Mid Cap Value Momentum ETF
Anteil0.16%
iShares Micro-Cap ETF
Anteil0.15%
Dividende
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.
Datum
Dividende
Stichtag für die Aktienregistrierung
Zahltag
Ex-Dividendentag
Keine Daten
Aktien-Split
Datum
Art
Verhältnis
Keine Daten
Datum
Art
Verhältnis
Keine Daten
